Navigation Links
NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
Date:4/1/2009

in December 2008. This patent will expire in 2026. NovaBay has recently filed additional patent applications that cover compositions of matter of additional Aganocide compounds, methods of use and formulations, and is preparing further applications in other areas.

Financial Results

Fourth Quarter 2008 Financial Results

License and collaboration revenue for the fourth quarter of 2008 increased 44% to $2.2 million from $1.5 million for the fourth quarter of 2007. License and collaboration revenue consists of the amortization of the upfront technology access fees previously paid, and reimbursements for the funding of research and development activities.

The net loss for the fourth quarter of 2008 was $(1.5) million, or $(0.07) per share, compared to a net loss of $(1.4) million, or $(0.09) per share, reported for the fourth quarter of 2007.

Research and development expenses for the quarter ended December 31, 2008 totaled $3.3 million, compared to $1.8 million for the quarter ended December 31, 2007. The increase was largely due to the timing of pre-clinical and clinical trials.

General and administrative expenses for the quarter ended December 31, 2008 were $0.5 million, compared to $1.2 million in the comparable 2007 period.

NovaBay ended the quarter and year with $12.1 million in cash and cash equivalents.

Full Year 2008 Financial Results

For the full year 2008, license and collaboration revenue totaled $6.7 million, compared to $5.9 for the year 2007.

NovaBay reported a net loss of $(8.1) million, or $(0.38) per share, for the full year 2008, compared to a net loss of $(5.4) million, or $(0.60) per share, for the full year 2007.

Research and development expenses for the full year 2008 were $9.6 million compared with
'/>"/>

SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. NovaBay and Galderma Enter Into Global Agreement to Develop and Commercialize NovaBays Novel Aganocide Drugs for Major Dermatological Conditions
2. NovaBay Pharmaceuticals Prices Initial Public Offering of Common Stock
3. Alseres Pharmaceuticals, Inc. Complies with NASDAQ Rule Regarding Recently Filed 10-K
4. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
5. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
6. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
7. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
8. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
9. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
10. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
11. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/v6klp2/nanobiotechnology ... PharmaBiotech,s new report "Nanobiotechnology Applications, Markets ... An increasing use of nanobiotechnology ... anticipated. Nanotechnology will be applied at all ... for optimal delivery to diagnostic applications in ...
(Date:9/2/2015)... DUBLIN , Sep. 02, 2015 ... ) has announced the addition of Jain PharmaBiotech,s ... Companies" to their offering. This ... as a characteristic that can be objectively measured ... or pathogenic processes as well as pharmacological responses ...
(Date:9/2/2015)... CUMBERLAND, R.I. , Sept. 2, 2015 /PRNewswire/ ... has been enrolled in the multicenter Phase 2 ... for the long-term treatment of recurrent subfoveal choroidal ... AMD).  NT-503 is a unique vascular endothelial growth ... versatile ECT implant. "This landmark proof-of-concept ...
(Date:9/2/2015)... , September 2, 2015 BiondVax ... of the National Institute of Allergy and Infectious Diseases (NIAID), ... the Department of Health and Human Services (HHS), to launch ... the United States in the 2015-16 timeframe. ... vaccine candidate, Multimeric-001 (M-001), as a primer vaccine, which would ...
Breaking Biology Technology:Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 2Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 3Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3
... HARRISBURG, Pa., Oct. 20 PresentCare, a technology ... AdherencePlus(TM) solution, an innovative approach to assist the ... medication non-adherence. The AdherencePlus solution is comprised ... communication technology combined with unprecedented human touch. Both ...
... , ROME, October 20 ... of World Osteoporosis Day, International Osteoporosis Foundation,(IOF) CEO ... the,globe to join the fight against osteoporosis. "Osteoporosis ... afford to ignore. Immediate measures must,be taken to ...
... 19 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc.,(OTC Bulletin Board: LTUS) ("Lotus" ... and licensed national seller of pharmaceutical,products in the People,s Republic ... Lotus,s priorities for the balance of 2009 are, ... do for its most valuable customers, ...
Cached Biology Technology:Medication Adherence Technology Combines with Patient Outreach Program to Yield Healthier Populations and Reduce Healthcare Costs 2Medication Adherence Technology Combines with Patient Outreach Program to Yield Healthier Populations and Reduce Healthcare Costs 3World Osteoporosis Day Call for Immediate Action to Prevent Fractures 2Lotus Pharmaceuticals, Inc. Announces 2010 Growth Strategy 2Lotus Pharmaceuticals, Inc. Announces 2010 Growth Strategy 3Lotus Pharmaceuticals, Inc. Announces 2010 Growth Strategy 4
(Date:8/17/2015)... 17, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market and creator of ... for Q4 2015. The new marketing campaign is being ... Amplitude Marketing Group ( http://amplitudemarketing.com/ ) and TPMG ( ... leader in retail driven marketing and brand awareness and ...
(Date:8/11/2015)... 11, 2015 Today, ZUK announced its Android ... well as expected revenues in 2015 that relate to sales of ... guidance of approximately 2,200 MSEK for 2015. Jörgen Lantto, ... prominent smartphone manufacturer in China ... selected FPC1 155 for Z1 ...
(Date:8/6/2015)... SAN JOSE, Calif. , Aug. 6, 2015 ... the leading developer of human interface solutions, today ... and TouchPad technologies on Windows 10. Microsoft leveraged ... fundamental to the operating system. ... and drivers are fully certified with Microsoft,s Precision ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... VA As the Colorado River winds through the Colorado ... of sediment. This sediment which once left the river,s ... Colorado "the reddish river" is a vital component to ... of the Hoover and Glen Canyon dams, which trap the ...
... significant upgrade that would enable it to produce high-quality, ... key material by a team of researchers that includes ... Texas A&M University. The material, which converts ... to produce an image, is the result of a ...
... Vulcan mind meld to share cognition: Virginia Tech Carilion ... and hot feelings may be more intimately connected than previously ... parts, like Spock, and separate emotional parts, like Kirk. But ... , director of the Human Neuroimaging Laboratory at ...
Cached Biology News:Texas A&M research contributes to improved ultrasound imaging 2Kirk, Spock together: Putting emotion, logic into computational words 2
ma. plate stack height 70mm...
... Angle rotor for use in ... CL3/CL3R, HN-SII or Centra MP4/MP4R. ... accepts 15 mL round bottom, ... tubes as well as popular ...
... Satellite Thermal Cycler (MBS) is ... for medium to high throughput ... the latest in satellite block ... PC control, resulting in a ...
...
Biology Products: